U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C28H40N4S.C4H4O4
Molecular Weight 580.781
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of FOROPAFANT FUMARATE

SMILES

OC(=O)\C=C\C(O)=O.CC(C)C1=CC(C(C)C)=C(C2=CSC(=N2)N(CCN(C)C)CC3=CC=CN=C3)C(=C1)C(C)C

InChI

InChIKey=VVMIAYBAROQMMT-WLHGVMLRSA-N
InChI=1S/C28H40N4S.C4H4O4/c1-19(2)23-14-24(20(3)4)27(25(15-23)21(5)6)26-18-33-28(30-26)32(13-12-31(7)8)17-22-10-9-11-29-16-22;5-3(6)1-2-4(7)8/h9-11,14-16,18-21H,12-13,17H2,1-8H3;1-2H,(H,5,6)(H,7,8)/b;2-1+

HIDE SMILES / InChI
Molecular Formula C28H40N4S
Molecular Weight 464.709
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description

Foropafant is a platelet-activating factor (PAF) antagonist which was developed by Sanofi. It was in clinical development for the treatment of asthma, thrombosis and ulcerative colitis. The development of the drug was discontinued due to lack of efficacy.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Platelet-activating factor receptor
3
Target ID: P25105
Gene ID: 5724.0
Gene Symbol: PTAFR
Target Organism: Homo sapiens (Human)
Antagonist
2849
 57.0 pM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Not Provided
511
Unknown

Approved Use

Unknown
Primary
Not Provided
511
Unknown

Approved Use

Unknown
Primary
Not Provided
511
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Activation of PAF receptor by oxidised LDL in human monocytes stimulates chemokine releases but not urokinase-type plasminogen activator expression.
2004-06
Platelet-leukocyte cross talk in whole blood.
2000-12
Role of tachykinins in castor oil diarrhoea in rats.
1997-06
Effect of SR 27417 on the binding of [3H]PAF to rabbit and human platelets and human polymorphonuclear leukocytes.
1993-05
Patents

Patents

US-5780468-A
2

Sample Use Guides

In Vivo Use Guide
In acute asthma study, foropafant was administered orally at 20 mg dosage
Route of Administration: Oral
In Vitro Use Guide
Foropafant displayed marked in vitro inhibition of PAF-induced oxidative burst in guinea pig macrophages (IC50 = 32 nM). Foropafant potently inhibited PAF-induced aggregation of rabbit and human platelets in vitro (IC50 = 0.10 and 0.50 nM, respectively).
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:14:27 GMT 2025
Edited
by admin
on Mon Mar 31 18:14:27 GMT 2025
Record UNII
77229931IM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FOROPAFANT FUMARATE
Common Name English
SR-27417A
Preferred Name English
1,2-ETHANEDIAMINE, N1,N1-DIMETHYL-N2-(3-PYRIDINYLMETHYL)-N2-(4-(2,4,6-TRIS(1-METHYLETHYL)PHENYL)-2-THIAZOLYL)-, (2E)-2-BUTENEDIOATE (1:1)
Systematic Name English
Code System Code Type Description
PUBCHEM
9938199
Created by admin on Mon Mar 31 18:14:27 GMT 2025 , Edited by admin on Mon Mar 31 18:14:27 GMT 2025
PRIMARY
FDA UNII
77229931IM
Created by admin on Mon Mar 31 18:14:27 GMT 2025 , Edited by admin on Mon Mar 31 18:14:27 GMT 2025
PRIMARY
CAS
136470-45-6
Created by admin on Mon Mar 31 18:14:27 GMT 2025 , Edited by admin on Mon Mar 31 18:14:27 GMT 2025
PRIMARY
Related Record Type Details
Structure of FOROPAFANT
PARENT -> SALT/SOLVATE
Structure of Fumaric acid
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of FOROPAFANT
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966